Baidu
map

Eur radiol:特发性肺纤维化患者活多久,哪些因素起着决定性作用?

2017-10-01 shaosai MedSci原创

特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一种不明原因的肺间质炎症性疾病,原因不明的肺泡纤维化和弥漫性肺间质纤维化均为其同义词。典型的IPF,主要表现为干咳、进行性呼吸困难,经数月或数年逐渐恶化,多在出现症状3~8年内进展至终末期呼吸衰竭或死亡。主要病理特点为肺间质和肺泡腔内纤维化和炎细胞浸润混合存在。尽管该病的发病机制还没有完全阐明,就其临床特征和病理

特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一种不明原因的肺间质炎症性疾病,原因不明的肺泡纤维化和弥漫性肺间质纤维化均为其同义词。典型的IPF,主要表现为干咳、进行性呼吸困难,经数月或数年逐渐恶化,多在出现症状3~8年内进展至终末期呼吸衰竭或死亡。主要病理特点为肺间质和肺泡腔内纤维化和炎细胞浸润混合存在。尽管该病的发病机制还没有完全阐明,就其临床特征和病理足以说明这是一种特征性的疾病。IPF的治疗尚缺乏客观的、决定性的预后因素或治疗反应,皮质激素(以下简称激素)或免疫抑制剂、细胞毒药物仍是其主要的治疗药物,但不足30%的病人有治疗反应,且可表现毒副反应。本研究回顾性分析是否特发性纤维化患者CT局部病变特点基线与1年后变化是否预测生存期,并将结果发表在Eur radiol上。

本研究共纳入了144例IPF患者,并在诊断时及1年后进行CT检查。利用基于纹理自动分析系统定量评价5个局部病变的程度。纤维化评分定义为蜂窝状和网格状高密度影的总量。利用Cox比例风险模型确定影响幸存期的独立预测因子。

共有106例患者(73.6%)在随访过程中死亡。单变量分析表明年龄、基线时用力肺活量、肺总量、肺一氧化碳弥散量、6分钟步行距离、去氧饱和、蜂窝状高密度影、网格状高密度影、纤维化评分、蜂窝状高密度影和纤维化评分的间期变化与幸存期显着相关。多变吧分析表明年龄、去氧饱和、纤维化评分及其间期改变是幸存期的独立预测因子(p = 0.003, <0.001, 0.001 and <0.001)。改善模型的C指数为0.768。

本研究表明,基于纹理分析的肺纤维化CT自动定量评价能够用来评估IPF患者幸存期的独立预测因子。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894632, encodeId=568d189463227, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Apr 19 12:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250958, encodeId=84e525095841, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:20 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249461, encodeId=da1e2494618f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Oct 01 19:40:20 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249442, encodeId=e3b9249442a3, content=特发性肺纤维化近年来越来越多.非常值得临床重视.不知道是因为诊断水平的提升还是发病率的增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Oct 01 16:44:22 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249413, encodeId=8ab924941384, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Oct 01 12:18:04 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249397, encodeId=d76824939e9b, content=特发性肺纤维化.难以治愈的病, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:19:10 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894632, encodeId=568d189463227, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Apr 19 12:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250958, encodeId=84e525095841, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:20 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249461, encodeId=da1e2494618f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Oct 01 19:40:20 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249442, encodeId=e3b9249442a3, content=特发性肺纤维化近年来越来越多.非常值得临床重视.不知道是因为诊断水平的提升还是发病率的增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Oct 01 16:44:22 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249413, encodeId=8ab924941384, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Oct 01 12:18:04 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249397, encodeId=d76824939e9b, content=特发性肺纤维化.难以治愈的病, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:19:10 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-07 sunfeifeiyang

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1894632, encodeId=568d189463227, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Apr 19 12:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250958, encodeId=84e525095841, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:20 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249461, encodeId=da1e2494618f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Oct 01 19:40:20 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249442, encodeId=e3b9249442a3, content=特发性肺纤维化近年来越来越多.非常值得临床重视.不知道是因为诊断水平的提升还是发病率的增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Oct 01 16:44:22 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249413, encodeId=8ab924941384, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Oct 01 12:18:04 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249397, encodeId=d76824939e9b, content=特发性肺纤维化.难以治愈的病, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:19:10 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 戒馋,懒,贪

    谢谢分享.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1894632, encodeId=568d189463227, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Apr 19 12:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250958, encodeId=84e525095841, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:20 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249461, encodeId=da1e2494618f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Oct 01 19:40:20 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249442, encodeId=e3b9249442a3, content=特发性肺纤维化近年来越来越多.非常值得临床重视.不知道是因为诊断水平的提升还是发病率的增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Oct 01 16:44:22 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249413, encodeId=8ab924941384, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Oct 01 12:18:04 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249397, encodeId=d76824939e9b, content=特发性肺纤维化.难以治愈的病, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:19:10 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 lovetcm

    特发性肺纤维化近年来越来越多.非常值得临床重视.不知道是因为诊断水平的提升还是发病率的增加

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1894632, encodeId=568d189463227, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Apr 19 12:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250958, encodeId=84e525095841, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:20 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249461, encodeId=da1e2494618f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Oct 01 19:40:20 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249442, encodeId=e3b9249442a3, content=特发性肺纤维化近年来越来越多.非常值得临床重视.不知道是因为诊断水平的提升还是发病率的增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Oct 01 16:44:22 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249413, encodeId=8ab924941384, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Oct 01 12:18:04 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249397, encodeId=d76824939e9b, content=特发性肺纤维化.难以治愈的病, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:19:10 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 清风拂面

    谢谢分享.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1894632, encodeId=568d189463227, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Apr 19 12:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250958, encodeId=84e525095841, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:20 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249461, encodeId=da1e2494618f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Oct 01 19:40:20 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249442, encodeId=e3b9249442a3, content=特发性肺纤维化近年来越来越多.非常值得临床重视.不知道是因为诊断水平的提升还是发病率的增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Oct 01 16:44:22 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249413, encodeId=8ab924941384, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Oct 01 12:18:04 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249397, encodeId=d76824939e9b, content=特发性肺纤维化.难以治愈的病, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:19:10 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 1e0f8808m18(暂无匿称)

    特发性肺纤维化.难以治愈的病

    0

相关资讯

Eur Respir J:家庭监测改善特发性肺纤维化的终点

由此可见,家庭监测可以提高研究终点评估的精确度,使IPF治疗在临床试验中的效率更高。

Eur Respir J:但肺气肿并发特发性肺纤维化的功能和预后效应分析!

IPF患者的肺气肿对预后没有影响,超出了纤维化和肺气肿的相加程度所能解释的范畴。关于肺纤维化的位置,肺气肿的分布决定了肺气肿的功能效应。

Am J Resp Crit Care:特发性肺纤维化患者呼吸道微生物与宿主之间存在怎样的相互作用?

宿主的转录组学的综合分析和微生物特征表明对于改变或更丰富的微生物宿主存在一个很明显的宿主反应。并且在纵向随访中这些反应仍然升高,表明下呼吸道的细菌群落可能作为特发性肺纤维化患者重复性肺泡损伤的持续刺激因子。

CHEST:特发性肺纤维化的综合治疗以及个性化治疗

正如CME在线活动(http://courses.elseviercme.com/chest16/647e)所示,特发性肺纤维化(IPF)是一种特定形式的慢性进行性纤维化肺疾病。目前,其发病原因不明。其是成人特发性间质性肺炎的最常见形式。美国医疗保障受益人的流行率在过去的14年中增长了一倍多。减少功能衰退和疾病进展的两种药物已经得到批准,2015年美国胸科协会对治疗IPF指南进行了更新,对疾病进行

Thorax:CXCL14是特发性肺纤维化Hh信号的候选生物标志物!!!

由此可见,CXCL14是一个全身性的生物标志物,可以用来识别Hh通路活性增加的IPF患者,并且监控IPF患者进行Hh拮抗剂治疗的药效学作用。

Lancet Respir Med:色甘酸钠吸入制剂用于特发性肺纤维化镇咳

研究认为特发性肺纤维化咳嗽是特殊的疾病特征,与慢性特发性咳嗽的发病机制可能不同,PA101吸入是有效的特发性肺纤维化镇咳方法

Baidu
map
Baidu
map
Baidu
map